European Pharmaceutical Review

JULY 25, 2023

Challenges for growth of the small molecule API market Intellectual property (IP) IP can be a significant barrier to entry into the small molecule API market, the authors noted. The authors highlighted this can be an obstacle for players in the small molecule sector. This can restrict a manufacturer’s capacity to make income.

Compounding 77

Compounding Generic Medicine 77

European Pharmaceutical Review

MARCH 9, 2023

Observing trends in the sector, Hotha noted: “the pharmaceutical regulatory space is shifting from traditional drug therapies to emerging targeted therapies that need specialised handling and considerations.” Rapid growth in oncology and antibody-drug conjugate markets continues to drive the development of CDMOs for HPAPIs.

Compounding 90

Compounding Dosage Communication 90

European Pharmaceutical Review

AUGUST 31, 2023

Overcoming challenges in patient safety, manufacturing and supply of radiopharmaceuticals As clinical trials progress and the first results are published, companies’ best candidates will emerge in the next five years. About the author Leila Jaafar-Thiel, PhD Dr Leila Jaafar-Thiel is the CEO and co-founder of Nuclidium AG.

Hospitals 78

Hospitals FDA Chemotherapy 78

European Pharmaceutical Review

SEPTEMBER 14, 2023

Future-proof your molecule Recent history shows that most successful biotechs have partnered with a contract development manufacturing organisation (CDMO) to provide the required expertise, resources, insights, and capacity. Given the critical role of partnerships in drug development, this is often where risks – and distrust – emerge.

Communication 81

Communication Patient Care 81

Pharmaceutical Technology

DECEMBER 20, 2022

Joseph McCall, article co-author and director, QA technical service, ADMA Biologics, explains why forming the group made sense both for the companies involved and for the industry: “We’ve found great advantage in sharing information and best practices so that you don’t have to make a mistake in order to learn from it. “The

Communication 52

Communication FDA 52

European Pharmaceutical Review

OCTOBER 12, 2023

A €25 million drug delivery manufacturing investment To boost capacity in producing user-friendly oral dosage forms, German CDMO HERMES Pharma announced in September it is investing €25 million in its manufacturing capabilities. Subject to planning permission, the site is expected to be opened by 2028. The new £26.4

Vaccines 84

Vaccines Dosage Pharmaceutical Companies Pharmaceutical Companies 84

European Pharmaceutical Review

JULY 20, 2023

The new general obligations of SoHO entities include: Registration as a SoHO entity with the national competent authority. Exchange of best practices and joint inspections of SoHO entities would be encouraged/supported by the EU Commission.

Labelling 63

Labelling Documentation Hospitals 63